Merck: China approves immunotherapy Keytruda for lung cancer
(CercleFinance.com) - Chinese regulators have approved Merck's Keytruda, the US drugmaker said on Monday, in another breakthrough for the company's blockbuster immunotherapy.
Merck's anti-PD-1 therapy has been approved by the National Medical Products Administration (NMPA), in combination with chemotherapy, for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer, the group said.
The approval represents a key advance in a country where lung cancer kills over 626,000 people each year, Merck said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
Merck's anti-PD-1 therapy has been approved by the National Medical Products Administration (NMPA), in combination with chemotherapy, for the first-line treatment of patients with metastatic nonsquamous non-small cell lung cancer, the group said.
The approval represents a key advance in a country where lung cancer kills over 626,000 people each year, Merck said.
Copyright (c) 2019 CercleFinance.com. All rights reserved.